Overview

Gender

male

Investor Type

Investment Partner

Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures.Prior to founding 5AM Ventures in 2002, Mr. Schwab was a Principal at Bay City Capital (BCC). After joining BCC in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx.Prior to joining BCC, Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities.

At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Anaphore, Cleave Biosciences, DVS Sciences, Flexion Therapeutics, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix) and Viveve.Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of the 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.